AMARIN CORP PLC\UK (AMRN) Company Report

Amarin reported total net revenue of $49.7 million in Q3 2025, a 17% increase year-over-year, driven by a 34% increase in U.S. net product revenue to $40.9 million.
The company significantly improved its financial discipline, with a Q3 2025 operating loss of $11.1 million, a 56% reduction from Q3 2024, and an operating margin of negative 22%, up from negative 60% in the prior year.
Amarin has transitioned to a fully partnered commercial model across international ex-U.S. markets, notably with Recordati in Europe, and implemented an organizational restructuring expected to yield $70 million in OpEx savings over the next year.
The company anticipates achieving positive free cash flow in 2026 and ended Q3 2025 with $286.6 million in cash and investments and no debt.
The FDA's recent revision of phenofibrate labeling, stating no cardiovascular benefit, is viewed as a critical step toward shifting clinical practice and an opportunity for VASCEPA, which has proven outcomes.

Oct 29, 2025, 12:00 PM

Amarin Reports Q3 2025 Financial Results with Revenue Growth and Improved Operating Loss

AMRN

Earnings

Guidance Update

Revenue Acceleration/Inflection

Amarin reported total net revenue of $49.7 million for Q3 2025, marking a 17% increase year-over-year, primarily driven by a 34% rise in U.S. net product revenue to $40.9 million.
The company's operating loss significantly improved to $11.1 million, a 56% reduction from Q3 2024, with operating margin improving to -22% from -60% in the prior year, largely due to a 47% reduction in SG&A from global restructuring.
Amarin is progressing with its fully partnered commercial model across international ex-U.S. markets, with the European transition to Recordati on track for completion by year-end 2025.
The company ended the quarter with $286.6 million in cash and investments and no debt, and anticipates achieving positive free cash flow in 2026.

Oct 29, 2025, 12:00 PM

Amarin Reports Q3 2025 Financial Results and Progresses on Partnered Commercial Model

AMRN

Earnings

Revenue Acceleration/Inflection

Layoffs

Amarin reported Q3 2025 total net revenue of $49.7 million, a 17% increase year-over-year, driven by a 34% increase in U.S. net product revenue to $40.9 million. The company's operating loss significantly improved to $11.1 million, 56% lower than Q3 2024.
The company has transitioned to a fully partnered commercial model across international ex-U.S. markets, with Recordati expected to fully manage European commercialization by the end of 2025. This strategic shift, combined with an organizational restructuring, is projected to yield $70 million in OpEx savings over the next year.
Amarin maintains over 50% share of the U.S. IPE market and regained exclusive status with a large national pharmacy benefit manager, expecting to retain major exclusives through at least the end of 2025.
The company anticipates achieving positive free cash flow in 2026 and ended Q3 2025 with $286.6 million in cash and investments and no debt.
The FDA's recent revision of phenofibrate labeling, highlighting a lack of cardiovascular benefit, is seen by Amarin as a critical step that could shift clinical practice towards proven therapies like VASCEPA.

Oct 29, 2025, 12:00 PM

Amarin Reports Q3 2025 Financial Results

AMRN

Earnings

Layoffs

Guidance Update

Amarin reported Total Net Revenue of $49.7 million for Q3 2025, an increase of 17% compared to Q3 2024, primarily driven by higher U.S. sales.
Operating Expenses decreased 20% to $33.3 million in Q3 2025, leading to an Operating Loss of $11.1 million, a 56% improvement from Q3 2024, largely due to the June 2025 restructuring.
The company's Net Loss for Q3 2025 was $7.7 million, or $0.02 per share, representing a 69% improvement compared to Q3 2024.
Amarin held $286.6 million in cash and investments at the end of Q3 2025.
The company is targeting sustainable positive free cash flow in 2026 and has completed its transition to a fully partnered commercialization model across all international markets.

Oct 29, 2025, 11:05 AM

Earnings Transcripts

Quarterly earnings call transcripts for AMARIN CORP PLC\UK.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop